This study is the first to suggest the tumour‐suppressive role of FUBP3 protein in CML and the association of microdeletions and decreased expression of the FUBP3 gene with adverse outcomes. Here, FUBP3 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.